BioNTech plans to produce vaccines in Singapore

BioNTech plans to produce vaccines in Singapore

May 12, 2021: -On Monday, BioNTech announced it would set up its Southeast Asia headquarters in Singapore and build a manufacturing facility in the city-state to produce its messenger RNA vaccines and different medicines to treat infectious diseases and cancer.

AstraZeneca to work on COVID-19 vaccine with Russia’s Sputnik V

AstraZeneca to work on COVID-19 vaccine with Russia’s Sputnik V

AstraZeneca to work on COVID-19 vaccine with Russia’s Sputnik V December 13, 2020 British pharmaceutical giant AstraZeneca said Friday it would soon start work with Russia’s Gamaleya Institute to investigate whether their two coronavirus vaccine candidates could be successfully combined. It comes after the developers of the Sputnik V Covid-19 vaccine approached AstraZeneca via Twitter […]

AstraZeneca sees 2022 growth as dividend increases

AstraZeneca sees 2022 growth as dividend increases

February 11, 2022: -On Thursday, AstraZeneca forecast higher 2022 sales and raised its annualized dividend after the drugmaker posted better-than-expected fourth-quarter profit as it gets a lift from its Covid-19 antibody treatment and cancer drugs.

AstraZeneca invests in the self-amplifying RNA technology

AstraZeneca invests in the self-amplifying RNA technology

September 24, 2021: -On Thursday, AstraZeneca struck a deal with the firm behind Imperial College London’s experimental Covid-19 vaccine to create and sell drugs based on its self-amplifying RNA technology platform in other disease areas.

Clinical trials are changing – for good

Clinical trials are changing – for good

In healthcare, the world of clinical trials seems to be up for some big moves – and permanent ones at that, HRI predicted. “In the face of a pandemic that seized nearly everyone, from patients to clinical trial coordinators, to stay home, at least momentarily, pharmaceutical and life sciences companies have been challenging: How much can be done remotely?” the report read. “Quite a bit, it turns out